Massachusetts-based Digilab Inc. and 3Dispense in Greenfield, a provider of fluidic and automated dispensing products are partnering to develop the next generation of bioprinters. The two companies expect this to address the tissue engineering needs of pre-clinical drug discovery, regenerative medicine, and clinical diagnostic markets.
"We are pleased to advance this teaming relationship with Digilab to service the needs of our life science and clinical clients," said Richard Parker, president of 3Dispense. “Having developed our first live-cell printing instruments over 10 years ago, the collaboration between our organizations should allow us to better provide solutions to the global tissue engineering community."
The new line of 3D bioprinters will build upon current modular designs enabling layered cell printing for true 3D printing employing the latest advancements in miniature valves, pumps, and dispensing technologies. The companies will collaborate to design and build multi-channel systems to deliver multiple cell types, growth factors, reagents, and other biomaterials that allow researchers to better recapitulate disease pathophysiology, mimic organ function, and print tissue and organs.
“This agreement leapfrogs traditional SynQuad technology-based bioprinting solutions and Digilab’s rich heritage delivering high resolution, bioink agnostic, multi-channel systems that provide greater than 95% cell viability,” said John Moore Ph.D. Digilab’s president and COO.
Current Issue - April 2024